The biodegradable segment by product is estimated to lead the market growth during the forecast period.
According to The Insight Partners market research study of “Asia Pacific Dermal Fillers Market Forecast to 2028 - COVID-19 Impact and Regional Analysis by Product, Material, Application, End User and Country.” The Asia Pacific dermal fillers market is expected to reach US$ 2,118.21 million by 2028 from US$ 949.90 million in 2021; it is estimated to grow at a CAGR of 12.1% from 2021 to 2028. The report highlights trends prevailing in the Asia Pacific dermal fillers market and the factors driving market along with those that act as hindrances.
Dermal fillers are significant, non-invasive alternative to surgical facelifts, and it improves the appearance of skin. The use of fillers in men has increased due to the rise in awareness and popularity about noninvasive procedures. A large male population is opting for various aesthetic treatments, from forehead sculpting to the chin and jawline augmentation. Since 1997, there has been a ~300% increase in cosmetic procedures performed on male patients. Neurotoxins and dermal fillers have been among the most common. Also, the market players are focusing on introducing innovative products through extensive strategic activities for dermal fillers treatment. These devices are likely to offer superior treatment outcomes compared to existing products in the market. For instance, Merz announced the launch of Belotero Lips, with products specifically designed for lip enhancement and perioral lines treatment. Thus, strategic activities and product innovations are expected to deliver an impetus to the growth of the dermal fillers market in Asia Pacific during the forecast period.
Countries in Asia Pacific are facing challenges due to increasing incidence of COVID-19. The COVID-19 pandemic has put a significant strain on the health systems of many countries in the region. Nationwide lockdowns imposed to contain the infection, along with physical distancing measures and restrictions on medical practice, have affected the training of resident doctors and other healthcare professional. At present, even in recovery phase, clinics are only seeing 50% of usual patient volume, and the number of treatments has also reduced by at least 50%. The Ministry of Health and Family Welfare of the Government of India issued guidelines that precluded OPD and elective surgeries during the pandemic. However, Japan witnessed a surge in demand for cosmetic surgeries and other procedures amid pandemics.
The Asia Pacific dermal fillers market, by product is segmented into biodegradable and non-biodegradable. The Asia Pacific dermal fillers market, by material is segmented into calcium hydroxylapatite, hyaluronic acid, collagen, poly-l-lactic acid, polymethylmethacrylate (PMMA), fat, other materials. Based on application, the Asia Pacific dermal fillers market is segmented into facial line correction treatment, lip enhancement, face lift, scar treatment, and others. Based on end user, the Asia Pacific dermal fillers market is segmented into dermatology clinics, multispecialty hospitals, ambulatory surgical centers, and others. Geographically, the Asia Pacific dermal fillers market can be sub-segmented into India, South Korea, China, Japan, Australia and Rest of Asia Pacific.
BIOHA LABORATORIES, BIOPLUS CO., LTD., BIOXIS pharmaceuticals, TEOXANE LABORATORIES, AbbVie Inc., Galderma, Merz Pharma, Suneva Medical, HUADONG MEDICINE CO., LTD, and Prollenium Medical Technologies are among the leading companies operating in the Asia Pacific dermal fillers market.